Grafa News and Videos — Page 425

Aon (NYSE:AON) signed a definitive agreement to acquire USI from KKR and other shareholders for $17 billion, expanding its U.S. insurance brokerage operations.

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera (zanidatamab-hrii) plus chemotherapy improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma.

GameStop (NYSE:GME) reported preliminary second quarter 2026 results showing expected net income of $290 million to $310 million, compared with $168.6 million in the prior-year period.

BeOne Medicines (NASDAQ:ONC) reported Phase 3 HERIZON-GEA-01 trial results showing ZIIHERA (zanidatamab) plus chemotherapy produced a statistically significant improvement in overall survival compared with trastuzumab plus chemotherapy in first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

IDEAYA Biosciences (NASDAQ:IDYA) reported that an FDA Type C meeting provided guidance for the planned global randomized Phase 3 trial of IDE849, a DLL3-targeting TOP1 antibody-drug conjugate for extensive stage small cell lung cancer.

So-Young (NASDAQ:SY) reported second quarter 2026 revenue of RMB505.2 million, up 33.4% year over year, driven mainly by growth in its branded aesthetic center business.

Nissan and Honda (NYSE:HMC) agreed to jointly develop vehicle computer parts and software for models planned to enter the market in fiscal 2029, with the companies sharing core electronic control units and software.

Alvotech (NASDAQ:ALVO) announced that the U.S. Food and Drug Administration accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector formats.

Brent crude futures rose 2% to $89.87 per barrel and U.S. West Texas Intermediate crude increased 1.74% to $84.85 after U.S. strikes on Iran’s Larak Island intensified concerns about energy flows through the Strait of Hormuz.

BioMarin (NASDAQ:BMRN) entered into binding global settlement terms with Ascendis Pharma A/S to resolve patent disputes involving Yuviwel, including a U.S. International Trade Commission investigation and litigation in multiple countries.